The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
MS Tag 2026
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Spenden
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Digital calender 2026
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
Neurofilaments – Small proteins of physiological significance and predictive power for future neurodegeneration and cognitive decline across the life span
NIL
Jahr
Publikationsjahr
2023
Autoren
Autorenliste der Publikation
Elmers J, Colzato LS, Akgün K, Ziemssen T, Beste C.
Verlag
Publisher-Information
Ageing Res Rev. 2023 Aug 22;90:102037.
Link
Zur Publikation (externer Server)
https://doi.org/10.1016/j.arr.2023.102037
Tags
Forschungsthemen
Multiple Sklerose
Neuroimmunologie
MSZ
NIL
2023
MSPEECH (multiple sclerosis monitoring through speech interaction in clinic and at home): a Living Lab study protocol for co-created, speech-based digital biomarkers in multiple sclerosis
MASC
Jahr
2026
Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes
Multiple Sclerosis
Jahr
2026
Peripheral redox biomarkers in multiple sclerosis: associations with phenotype, cognition, and fatigue
Multiple Sclerosis
Jahr
2026
Neurofilament-Leichtkette (sNfL) als Instrument zur Beurteilung der Krankheitsaktivität und des Therapieansprechens bei Multipler Sklerose (MS)
NIL
Jahr
2026
From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis
NIL
Jahr
2026
